within Pharmacolibrary.Drugs.ATC.A;

model A10BD18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 700 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.09,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Metformin and gemigliptin is a fixed-dose combination oral antidiabetic medication used in the management of type 2 diabetes mellitus. Metformin is a biguanide that decreases hepatic glucose production and increases insulin sensitivity, while gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones, thereby improving glycemic control. This combination is approved and used clinically in several countries for patients who require both agents to achieve adequate glycemic control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were estimated for healthy adult subjects based on published PK profiles for metformin and gemigliptin administered together; no study was identified reporting full compartmental model parameters for the fixed-dose combination under ATC A10BD18.</p><h4>References</h4><ol><li><p>Jeong, SI, et al., &amp; Lee, S (2023). Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. <i>British journal of clinical pharmacology</i> 89(6) 1780–1788. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15632&quot;>10.1111/bcp.15632</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36496349/&quot;>https://pubmed.ncbi.nlm.nih.gov/36496349</a></p></li><li><p>Lee, SW, et al., &amp; Yu, KS (2019). Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination . <i>International journal of clinical pharmacology and therapeutics</i> 57(2) 117–124. DOI:<a href=&quot;https://doi.org/10.5414/CP203289&quot;>10.5414/CP203289</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30574864/&quot;>https://pubmed.ncbi.nlm.nih.gov/30574864</a></p></li><li><p>Choi, HY, et al., &amp; Bae, KS (2014). Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 52(5) 381–391. DOI:<a href=&quot;https://doi.org/10.5414/CP202038&quot;>10.5414/CP202038</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24495314/&quot;>https://pubmed.ncbi.nlm.nih.gov/24495314</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BD18;
